Medical device maker Abbott Laboratories (NYSE: ABT) on Thursday reported a 4% increase in sales for the fourth quarter of FY25. The company also issued its full-year 2026 guidance.
Sales increased 4.4% year-over-year to $11.46 billion in the fourth quarter, with a 3% growth in organic sales. For fiscal 2026, Abbott expects organic sales growth to be in the range of 6.5% to 7.5%.
Excluding special items, net earnings rose to $1.50 per share in the December quarter from $1.34 per share in the prior-year quarter. The company projects full-year adjusted earnings in the range of $5.55 per share to $5.80 per share, which reflects 10% growth at the midpoint
On a reported basis, net income was $1.78 billion or $1.01 per share in the fourth quarter, vs. $9.2 billion or $5.27 per share in Q4 2024.
“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future,” said Robert Ford, Abbott’s CEO.